Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 589 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05623150Recruiting
Biopsy-based study for alcohol and metabolic liver disease
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
NiceAges 18 years+ - NCT05652920RecruitingPhase 1/Phase 2
CAR T-cell therapy for liver cancer that has GPC3
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–70 - NCT05690048RecruitingPhase 2
Fecal transplant to help liver cancer respond to standard drugs
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT05714124Recruiting
Testing liver procedures to treat tumors when surgery isn’t possible
This trial studies different ways to place treatments inside the liver to control liver tumors when they can’t be removed with surgery or ablation. It may help certain people by improving how well the tumor is treated while keeping liver function safer.
MilanAges 18 years+ - NCT05718492Recruiting
Tested HAIC for liver cancer after prior immunotherapy
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
Guangzhou, GuangdongAges 18–75 - NCT05733598RecruitingPhase 2
RP2 plus standard treatment for advanced liver or bile cancers
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
Beverly Hills, CaliforniaAges 18 years+ - NCT05751343RecruitingPhase 2
Test atezolizumab and bevacizumab with liver cancer procedures
This Phase 2 trial tests whether atezolizumab plus bevacizumab, given along with liver cancer treatment procedures (TACE/HAIC), can help people with advanced liver cancer that cannot be removed by surgery. It mainly looks at whether these medicines can control the cancer more effectively and safely.
Guangzhou, GuangdongAges 18–75 - NCT05763277Recruiting
Predicting early response to atezolizumab plus bevacizumab
This study tries to predict how well your cancer responds early after starting a treatment called atezolizumab plus bevacizumab. If you qualify, your information may help doctors choose better treatments sooner for people with advanced liver cancer.
SeoulAges 18–80 - NCT05794048Recruiting
Study of blood and tumor features in liver and pancreatic cancers
This trial looks at a patient’s “metabolic profile” (how the body’s chemicals are used) in people with certain liver and pancreatic tumors. It may help doctors better understand these cancers and improve how they are evaluated for treatment.
ClichyAges 18 years+ - NCT05803928RecruitingPhase 1
Ablation plus lenvatinib and anti-PD-1 to prevent liver cancer return
This early-phase study tests whether adding medicines to ablation (heating/freezing to destroy liver tumors) can keep liver cancer from coming back. It’s for people whose liver cancer recurred after prior surgery/ablation but still fits specific criteria, with the goal of improving disease control.
Guangzhou, GuangdongAges 18–75 - NCT05870969Recruiting
Digital monitoring to catch liver cancer risk early
This study tests a digital (computer/phone-based) system to help track people with higher risk of liver cancer so cancers can be found earlier. It may help by guiding regular check-ins and making early diagnosis more efficient.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05882370RecruitingPhase 2
Immunotherapy plus TIPS for liver cancer with blocked portal vein
This study tests whether adding the immunotherapy drug cadonilimab (and a related treatment plan) plus TIPS can help people with advanced liver cancer that has a tumor clot causing portal vein pressure problems. It aims to improve disease control while managing the circulation pressure in the liver.
Guangzhou, GuangdongAges 18–75 - NCT05887661Recruiting
Personalized low-volume blood pressure care during laparoscopic liver surgery
This study looks at a customized blood-pressure and fluid strategy to help patients during laparoscopic liver tumor removal. It may help reduce complications related to blood loss and organ stress during surgery.
Nanjing, JiangsuAges 18 years+ - NCT05971108Recruiting
Check a blood test system to catch liver cancer early
This study will test a real-world blood testing system (Elecsys GAAD) to improve surveillance and earlier detection of liver cancer in people who already have liver scarring (cirrhosis). If it works well, it could help find liver cancer sooner and potentially improve outcomes.
Manchester, Greater ManchesterAges 18 years+ - NCT05984511Recruiting
Combined treatment for liver cancer with portal vein tumor thrombus
This trial tests whether adding immunotherapy (atezolizumab/bevacizumab) and a type of internal radiation (I-125 seeds) to standard chemoembolization (TACE) can help people with liver cancer that has spread into the main liver blood vessel (portal vein). It aims to control the tumor and improve outcomes.
Guangzhou, GuangzhouAges 18–75 - NCT05992584RecruitingPhase 2
Lenvatinib, sintilimab, and SIRT for liver cancer
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a procedure called SIRT (radioactive beads) for people with liver cancer that can't be surgically removed. The goal is to see if this triple approach works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT05994859Recruiting
SIRT for potentially removable liver cancer
This trial tests a targeted radiation treatment (SIRT) for people with liver cancer that is still confined to one side of the liver and has not been treated before. The goal is to see if SIRT can shrink the tumor enough to make surgical removal possible.
Guangzhou, GuangdongAges 18–75 - NCT06005740RecruitingPhase 1
Study of TORL-4-500 for advanced solid tumors
This trial tests a new investigational drug, TORL-4-500, for people with advanced solid tumors that have not responded to other treatments. It aims to find a safe dose and see if the drug can help shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06007846RecruitingPhase 2/Phase 3
Memantine for advanced liver cancer and cirrhosis
This trial tests if memantine, a medication typically used for memory problems, can help people with advanced liver cancer and cirrhosis. It is for those who cannot have standard aggressive treatments.
Fairfax, VirginiaAges 18 years+ - NCT06015022RecruitingPhase 2
Green tea extract to prevent liver cancer in cirrhosis
This trial tests whether a green tea extract called EGCG can prevent liver cancer in people with cirrhosis. It looks at how the extract affects liver cell changes that could lead to cancer.
Dallas, TexasAges 18 years+ - NCT06031285RecruitingPhase 2
Perioperative immunotherapy plus TACE-HAIC for liver cancer with portal vein tumor thrombus
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
Guangzhou, GuangdongAges 18–75 - NCT06041477RecruitingPhase 3
Combining treatments for liver cancer before surgery
This study tests whether giving targeted therapy and immunotherapy at the same time or one after the other is better for shrinking liver tumors that can't be removed right now but might be removable after treatment.
Guangzhou, GuangdongAges 18–75 - NCT06061276Recruiting
Combined therapy for large liver cancer with limited spread
This trial tests a combination of treatments—bland transarterial embolization (bTAE), hepatic artery infusion chemotherapy (HAIC), and systemic therapy—for people with large liver cancers that have limited spread. It might be an option if you have a big tumor and your liver is still working well.
Guanzhou, GuangdongAges 18–75 - NCT06077591Recruiting
Genetic and organoid testing to guide cancer treatment
This trial uses advanced testing (genetic sequencing and lab-grown tumor models) to find the best treatment for people with advanced solid tumors that haven't responded to at least one standard treatment. The goal is to personalize therapy based on your tumor's unique features.
Hong Kong, N.T.Ages 18–100
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 589 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.